Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,728 across all filing types
Latest filing 2015-03-11 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
募集资金使用情况鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as a "募集资金使用情况鉴证报告" which translates to "Verification Report on the Use of Raised Funds." It includes detailed information about the company's raised funds, their storage, usage, and management for the fiscal year 2014. The report references regulatory requirements from the China Securities Regulatory Commission and Shanghai Stock Exchange regarding the management and use of raised funds. It contains audit opinions from a registered accounting firm, detailed tables of fund usage, investment projects, and compliance with relevant regulations. This type of document is a specialized audit or verification report focusing on the use of capital raised by the company, rather than a full annual report or earnings release. It is not a simple announcement or certification but a comprehensive audit-related report on fundraising usage. Therefore, it fits best under the category of Audit Report / Information (AR).
2015-03-11 Chinese
2014年度独立董事述职报告
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Directors' Report" for the year 2014 from Kunming Pharmaceutical Group Co., Ltd. It details the independent directors' attendance, opinions, and evaluations regarding the company's governance, audit, and major corporate actions during the year. It includes references to audit reports, board meetings, and independent opinions on financial and governance matters. The document is a detailed report on the independent directors' duties and opinions rather than a full annual report or audit report itself. It is not a brief announcement or a certification letter but a substantive report on board/management information, specifically focusing on independent directors' activities and opinions. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length (3869 characters) is under 5000 but contains detailed content, so it is not a mere announcement (RPA).
2015-03-11 Chinese
2014年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Evaluation Report" for the year 2014 by Kunming Pharmaceutical Group Co., Ltd. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2014, including financial and non-financial internal control deficiencies, standards for defect recognition, and conclusions on the internal control status. The document is a standalone report focused on internal control evaluation rather than a full annual report or audit report. It does not appear to be an announcement or a brief notice but a substantive report on internal control evaluation. This fits the category of Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles and internal control evaluations, excluding full annual reports. The document length is 2602 characters, which is consistent with a detailed report but not a full annual report. Therefore, the classification is AR with high confidence. FY 2014
2015-03-11 Chinese
七届十七次监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the supervisory board (监事会) of Kunming Pharmaceutical Group Co., Ltd. It discusses the review and approval of the 2014 annual supervisory board work report, the 2014 financial settlement report, the 2014 annual report and its summary, internal control self-evaluation report, and accounting policy changes. It also includes the supervisory board's independent opinion on the 2014 annual report, confirming compliance with laws and regulations and the accuracy of the report. The document is relatively short (1213 characters) and serves as an official announcement of supervisory board resolutions and opinions related to the annual report, rather than the full annual report itself. Therefore, it is best classified as a Regulatory Filing (RNS) because it is an official announcement related to the annual report but does not contain the full report or detailed financial statements.
2015-03-11 Chinese
2014年公开增发A股股票募集资金存放与实际使用情况的专项核查报告
Audit Report / Information Classification · 95% confidence The document is a detailed report from a securities firm (招商证券股份有限公司) acting as the sponsor and lead underwriter for Kunming Pharmaceutical Group Co., Ltd. It focuses on the 2014 annual special audit of the storage and actual use of funds raised from a public offering of A shares in 2013. The report includes detailed financial data on the amount raised, usage of funds, project progress, changes in investment projects, idle funds, and compliance with relevant laws and regulations. It also contains tables with financial figures and investment project details. The document is not a brief announcement or a certification letter but a substantive audit report on the use of capital raised by the company. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and results of internal or regulatory checks related to accounting and fund usage, excluding full annual reports. The document length (9659 characters) and content confirm it is a full report rather than a mere announcement or regulatory filing. Therefore, the appropriate classification is AR with high confidence. FY 2014
2015-03-11 Chinese
2015年日常关联交易预估公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding the company's estimated daily related-party transactions for the year 2015. It includes information about the approval process by the board, details of related parties, transaction amounts, pricing policies, and the impact on the company. The document is not a full financial report but rather a disclosure about related-party transactions, which is a regulatory announcement. It does not contain comprehensive financial statements or management discussion and analysis. The document length is over 7,000 characters, indicating it is a substantive announcement rather than a brief notice. Given the nature of the content focusing on related-party transactions and their estimates, this fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2015-03-11 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.